TY - JOUR
T1 - Denosumab in breast cancer
AU - Lipton, Allan
PY - 2011/2
Y1 - 2011/2
N2 - Bone destruction is mediated by osteoclasts, whose formation, function, and survival requires the receptor activator of NF-kB ligand (RANKL). Denosumab is a fully human monoclonal antibody to RANKL, thereby inhibiting osteoclast-mediated bone destruction, and blocks the vicious cycle of cancer-mediated bone disease. In breast cancer patients with bone metastases, denosumab was superior to zoledronic acid in delaying time to first on-study skeletal-related event (SRE; HR∈=∈0.82; P∈=∈0.01 superiority) and time to first and subsequent on-study SREs (HR∈=∈0. 77; P∈=∈0.001). Overall survival, disease progression, and serious adverse events were similar between groups.
AB - Bone destruction is mediated by osteoclasts, whose formation, function, and survival requires the receptor activator of NF-kB ligand (RANKL). Denosumab is a fully human monoclonal antibody to RANKL, thereby inhibiting osteoclast-mediated bone destruction, and blocks the vicious cycle of cancer-mediated bone disease. In breast cancer patients with bone metastases, denosumab was superior to zoledronic acid in delaying time to first on-study skeletal-related event (SRE; HR∈=∈0.82; P∈=∈0.01 superiority) and time to first and subsequent on-study SREs (HR∈=∈0. 77; P∈=∈0.001). Overall survival, disease progression, and serious adverse events were similar between groups.
UR - http://www.scopus.com/inward/record.url?scp=79551534789&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79551534789&partnerID=8YFLogxK
U2 - 10.1007/s11912-010-0135-y
DO - 10.1007/s11912-010-0135-y
M3 - Article
C2 - 21053109
AN - SCOPUS:79551534789
SN - 1523-3790
VL - 13
SP - 1
EP - 4
JO - Current oncology reports
JF - Current oncology reports
IS - 1
ER -
